Tenax Therapeutics, INC Schedule 13G passive stakes

Vestal Point Capital, LP and Ryan Wilder have disclosed a 9.9% passive beneficial ownership stake in Tenax Therapeutics, Inc., primarily through common stock and warrants.

Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly reported a 6.9% passive beneficial ownership in Tenax Therapeutics, Inc.

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, reported a 7.4% beneficial ownership stake in Tenax Therapeutics, Inc.

Ikarian Capital and Neil Shahrestani have reported a 21.2% beneficial ownership stake in Tenax Therapeutics, Inc., holding 967,600 shares of common stock.

Raymond Debbane and affiliated entities, collectively known as the Invus Group, have reported a combined beneficial ownership of 9.4% in Tenax Therapeutics, Inc. common stock.

Venrock Healthcare Capital Partners and affiliates disclose continued beneficial ownership of 9.9% of Tenax Therapeutics, Inc. common stock.

Janus Henderson Group plc has filed an amendment to its Schedule 13G, reporting a 4.0% beneficial ownership stake in Tenax Therapeutics, Inc.

Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly disclosed a 5.6% beneficial ownership stake in Tenax Therapeutics, Inc. common stock.

A group of Venrock Healthcare Capital Partners entities and individuals have filed an amended Schedule 13G, disclosing a continued beneficial ownership of 9.9% in Tenax Therapeutics, Inc.'s common stock as of March 31, 2025.

RTW Investments, LP and its Managing Partner, Dr. Roderick Wong, have disclosed a 9.99% passive beneficial ownership stake in Tenax Therapeutics, Inc., totaling 418,440 shares.

Janus Henderson Group PLC and its affiliate, Janus Henderson Biotech Innovation Master Fund Ltd, have disclosed a passive beneficial ownership of 9.9% in Tenax Therapeutics, Inc. through an amended Schedule 13G filing.

Dellora Investments Master Fund LP, Dellora Investments LP, and Kevin Pyun have filed an amended Schedule 13G, disclosing their beneficial ownership of common stock in Tenax Therapeutics, Inc., with stakes reaching up to 8.8%.

S.H.N. Financial Investments Ltd. has filed an amendment to its Schedule 13G, disclosing a 4.99% beneficial ownership stake in Tenax Therapeutics, Inc. as of December 31, 2024, primarily through warrants.

Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a 5.4% beneficial ownership stake in Tenax Therapeutics, Inc. as of December 31, 2024.

Dellora Investments LP and its affiliates have disclosed a significant passive ownership stake in Tenax Therapeutics, Inc., with holdings reaching up to 10.3% of the common stock.